We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Lidco Group Plc | LSE:LID | London | Ordinary Share | GB0030546849 | ORD 0.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 11.75 | 11.50 | 12.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
28/3/2019 08:47 | POST REMOVED | buywell2 | |
28/3/2019 08:41 | It would be far easier and cheaper in long run for Edwards to take over Lidco. | 7767 | |
28/3/2019 07:12 | POST REMOVED | buywell2 | |
28/3/2019 06:59 | Good morning buywell2 and all :) Thank you for your post but I am still not clear as to why Edwards would struggle to offer a similar HUP pricing plan like LID ? Re your post...."It would cost Edwards an arm and a leg to change re what they make now..." I am not sure as to why Edwards or anyone else would need to change their manufacturing process or products ? I agree that LID are very likely to get acquired as bigger companies like revenue visibility and recurrent business. Lidco's tiny market cap coupled with a relatively small free float makes it a sitting duck. The daily trading / liquidity is low and hence any good news or major developments will result in a sharp share price spike. It has been difficult to get any decent quantity, though I managed to buy 245,531 yesterday at 5.08p. I intend to average up based on developments but have reached a decent initial holding position. Good luck all :) | multibagger | |
28/3/2019 04:29 | POST REMOVED | buywell2 | |
27/3/2019 18:02 | buywell2 - Like you metaphors - Very true but all insecects can be squashed - however possibly easier to seduce them with sugar- | pugugly | |
27/3/2019 17:06 | POST REMOVED | buywell2 | |
27/3/2019 16:42 | POST REMOVED | buywell2 | |
27/3/2019 07:24 | Total directors new purchases 400,000 shares at cost of some £18K - I suspect significanly less than some gamblers on this thread picked up during the recent crash but good to see their confidence but would have been more impressive if there had been another zero on both numbers and costs (all imo) - However market now very tight and very little stock available without moving the price significantly so probably good to nibble without ramping the price - The Cynic. | pugugly | |
27/3/2019 07:07 | Good morning Buywell2 and all ! Maybe a naive question - given that the HUP/SaaS model is so successful, what stops Edwards and/or Maquet replicating the same pricing model just to hold on to market share ? Edit: Good to see some Director/ PMDR share purchases from open market. | multibagger | |
27/3/2019 07:06 | POST REMOVED | buywell2 | |
26/3/2019 22:59 | POST REMOVED | buywell2 | |
26/3/2019 16:29 | The old CEO who gave way to Matt Sassone loaded his pension with shares so there's confidence in the future of the company share price. | 7767 | |
26/3/2019 15:42 | POST REMOVED | buywell2 | |
26/3/2019 11:17 | POST REMOVED | buywell2 | |
26/3/2019 11:12 | POST REMOVED | buywell2 | |
26/3/2019 10:30 | POST REMOVED | buywell2 | |
26/3/2019 10:21 | POST REMOVED | buywell2 | |
26/3/2019 08:19 | mb_ Thanks for spotting - All depends in level of royalty -v- own sales and hopefully the licenced stream does not eat the own sales momentum and thus decrease own revenues and thus margin - Sales costs are a high overhead and not easily reduced without impacting net revenue. | pugugly | |
26/3/2019 08:15 | POST REMOVED | buywell2 | |
26/3/2019 08:12 | POST REMOVED | buywell2 | |
26/3/2019 07:58 | Good morning Pugugly and all :) Tucked away in the RNS...was a possible separate "algo white label" revenue stream being tested in the market(IMHO)...but clearly early days... "...LiDCO's core technologies are patented and the Board sees licensing the Group's technology as another way to access the market. The LiDCO algorithm has been licensed on a non-exclusive basis to a major corporate partner in the USA in return for future royalty payments...." | multibagger | |
26/3/2019 07:52 | Nothing not already known so no surprises - Still however loss making and all (imo) now depends on whether the HUP roll out can continue to gain momentum - If so then share price should rapidly appreciate - If not then ................!! | pugugly | |
26/3/2019 07:51 | Edited (due to formatting reasons) excerpt from RNS The growth of the HUP business is illustrated in the table below: HUP Monitors Placed Jan-18 Apr-18 Jul-18 Oct-18 Jan-19` 20-Mar-19 96 98 130 135 164 212 ------- ------- ------- ------- -------- ---------- Annual Contract Value in GBPk 730 832 1,123 1,181 1,403 1,817 ------- ------- ------- ------- -------- ---------- | multibagger | |
26/3/2019 07:45 | RNS Number : 9506T 26 March 2019 LIDCO GROUP PLC ("LiDCO" or the "Company" or the "Group") Final results Results to 31 January 2019 LiDCO (AIM: LID), the hemodynamic monitoring company, announces its audited Final Results for the year ended 31 January 2019. The Group has delivered good progress for the roll out of its High Usage Programme ('HUP'). Whilst this transition has had a short-term impact on revenues, the Group is now well-positioned for strong growth in the current financial year. Operational highlights -- Recurring revenues increased to 81% of total LiDCO product revenues (2018: 71%) -- Global contracted base of HUP monitors increased to 164 (2018: 96) monitors generating total annualised license revenues of GBP1.40m (2018: GBP0.73m) -- US contracted base of HUP monitors increased to 95 monitors (2018: 58 units); US recurring revenues grew nearly 50% to GBP1.27m (2018: GBP0.85m) -- Three of LiDCO's larger UK customers signed multi-year HUP contracts - representing GBP0.45m (14%) of LiDCO's 2018/19 recurring revenues in the UK -- Exclusive UK distribution agreements signed with Maicuff, Antmed and Xavant -- Submission for new monitoring platform made to Chinese regulatory authorities -- New exclusive distributors signed in Sweden, Finland, Romania, Taiwan, and Sri Lanka Financial highlights -- Total revenue of GBP7.32m (2018: GBP8.27m). LiDCO product revenue (excluding third-party products) was down 10% to GBP6.19m (2018: GBP6.87m), the reduction due to a number of non-recurring factors -- HUP deferred revenues of GBP0.77m up 28% (2018: GBP0.60m) -- Gross margin (excluding third-party products) of 74.5% (2018: 73%) -- Adjusted loss before tax* of GBP1.99m (2018: loss GBP1.84m) -- Reported loss before tax of GBP2.14m (2018: loss GBP2.22m) -- Loss per share of 0.80 pence (2018: loss per share 0.86 pence) -- Net cash outflow before financing of GBP1.51m (2018: GBP1.67m), H2 cash outflow GBP0.32m (2018: GBP0.76m) -- Debt free with cash at year-end of GBP1.72m (2018: GBP3.23m) * adjusted for share-based payments of GBP0.1m in both 2018 and 2019 and one-off stock write-down of GBP0.3m in 2018 Post year end -- Further 48 HUP monitors signed, bringing the global contracted base of HUP monitors to 212, generating total annualised license revenues of GBP1.82m -- Appointment of Tim Hall as Chief Financial Officer -- New master distributor appointed in Latin America Commenting on the results Matthew Sassone, Chief Executive Officer, said: "We continue to make good progress with the transition to the HUP business model and it's pleasing to see a further 48 HUP monitors signed since the year end. Since launching HUP in mid-2017 we have built a recurring revenue base from HUP of over GBP1.8m. The growing base of HUP monitors and the underlying fundamentals of the business positions the Company for strong growth in the current financial year and beyond." | multibagger |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions